Instrument Inactif

Communiqués Tryp Therapeutics Inc. Canadian Securities Exchange

Actions

TRYP

CA89854F1062

Recherche biotechnologique et médicale

Communiqués

17/05/24	Tryp Therapeutics Files Amended Financial Statements for the Six Months Ended February 29, 2024	NE
01/09/21	CORRECTION FROM SOURCE: Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference	NE
01/09/21	Tryp Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference	NE
24/08/21	Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida	NE
18/08/21	Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor	NE
10/08/21	Tryp Therapeutics Partners with Calvert Labs to Conduct Exploratory Studies for Proprietary Psilocybin Formulations	NE
03/08/21	Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference	NE
29/07/21	Tryp Therapeutics Announces Q3 2021 Financial Results	NE
26/07/21	Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor	NE
21/07/21	Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan	NE
15/07/21	Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021	NE
07/07/21	Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations	NE
24/06/21	Tryp Therapeutics to Present at the Psych Investor Summit	NE
08/06/21	Tryp Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference	NE
02/06/21	Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference	NE
25/05/21	Tryp Therapeutics Partners with Alcami for Proprietary Formulations	NE
10/05/21	Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support	NE
03/05/21	Tryp Therapeutics Partners with Fluence for Psychotherapy Design	NE
29/04/21	Tryp Therapeutics Announces Q2 2021 Financial Results	NE
20/04/21	Tryp Therapeutics Reports on Key Milestones for 2021	NE
15/04/21	Tryp Therapeutics to Host Investor Day on April 22	NE
05/04/21	Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility	NE
02/04/21	Tryp Therapeutics Announces Amendment to Option Plan and Option Grant	NE
01/04/21	Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer	NE
18/03/21	Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics	NE